A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients

Inclusion criteria

• Male or females outpatients with primary open-angle glaucoma or ocular hypertension;
• Subjects who have received Latanoprost at least 4 weeks, and in the end of screening period, subject's Intra-Ocular Pressure is ≧18mmHg (choice of one eyes is possible), or Investigator judges the reduction of IOP is insufficient of individual subject.
• Aged between ≧ 20 and ≦80 years old when giving informed consent to the study.

Exclusion criteria

• Hypersensitivity to either oral or topical beta-blocker therapy or to any ophthalmic solution used in the study;
• Patients wearing contact lenses;
• Patients with severe dry eyes;
• Patients who had ophthalmic surgery including cataract surgery, trabeculotomy or trabeculectomy within three months of study start;
• Patients who had laser trabeculoplasty within 2 months before starting study;
• Patients who had corneal contamination, and acute ophthalmic infection, or inflammatory ophthalmic disorder 2 months before starting study;
• Patients who had herpetic keratitis or corneal ulcer within 2 months before starting study;
• Patient who are receiving systemic administration of drugs that may have and effect on IOP;
• Patients who have poorly controlled heart failure, sinus bradycardia, atrioventricular block (1 and 2 grade), or cardiogenic shock;
• Patients with brochial asthma, bronchospasm or severe chronic obstructive pulmonary disease or a history thereof;
• Patients with poorly controlled diabetes or diabetic ketoacidosis or metabolic acidosis;
• Patients with aortic stenosis, Raynaud's syndrome, intermittent claudication, or pheochromocytoma;
• Patients with myasthenia gravis;
• Patients with severe hepatic or renal disorder judged by investigator;
• Patients who have confirmed or potential pregnancy, current lactation, or wish to become pregnant during the study period;
• Patients who have treatment with any investigational drug when giving informed consent;
• Patients with significant alcohol, drug or medication abuse as judged by investigator;
• Patients whom investigator judges as subjects to be inappropriate for the clinical study (e.g., patient with severe complication)